Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be ...

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have ...

The second quarter of 2025 begins under the shadow of sharp rotations in capital, increased political risk, and growing ...

A simmering mistrust of medical science and scientific institutions that had been long building in the United States boiled ...